Elotuzumab for the treatment of multiple myeloma - Wikidata - wikimedia - TriplyDB

Elotuzumab for the treatment of multiple myeloma

Elotuzumab for the treatment of multiple myeloma

http://www.wikidata.org/entity/Q26740278

about

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.CIK Cells and HDAC Inhibitors in Multiple Myeloma.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.Tumor immunotherapy: New aspects of natural killer cells.Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

P2860

Q38661370-71B5B457-E518-44DA-B290-9C783C0BE8DE Q38705046-1646440D-6114-4D1B-A4FD-9176640C7F6F Q41370609-E207B867-6B3E-40B8-ADA3-16E20E7D3915 Q55059834-E63E806A-37CA-4122-85EA-C9E2B6C5AB3F Q55107050-B6CA3DE3-EC4F-4B99-BC4A-BD470AE83EAB Q55140257-DCEBACBD-D080-4FE3-AB0A-C8E93C10E738 Q55642634-EFD791C1-991E-4707-8B39-0E66CC5A2332 Q58786182-5E08F143-7D5A-4D49-966C-A85E8AAD931D

P2860

Elotuzumab for the treatment of multiple myeloma

http://www.wikidata.org/entity/Q26740278

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Elotuzumab for the treatment of multiple myeloma

@ast

Elotuzumab for the treatment of multiple myeloma

@en

Elotuzumab for the treatment of multiple myeloma

@nl

type

label

Elotuzumab for the treatment of multiple myeloma

@ast

Elotuzumab for the treatment of multiple myeloma

@en

Elotuzumab for the treatment of multiple myeloma

@nl

prefLabel

Elotuzumab for the treatment of multiple myeloma

@ast

Elotuzumab for the treatment of multiple myeloma

@en

Elotuzumab for the treatment of multiple myeloma

@nl

P1433

Q26740278-1122FE91-74AF-4902-8E48-C9BD91835841

P1476

Q26740278-1A8E1D00-4E01-4D3B-B080-73A7083B7FA1

P2093

Q26740278-158F298A-880C-4E1C-9067-01D7A01A2F7F

Q26740278-B92E2155-0DC2-46B4-B752-30B85CDECAE5

Q26740278-CED268A1-241C-4FF7-87AD-2C6C68F9BFA3

Q26740278-EE84B37E-A15F-41E0-91E7-188D6EC608C5

P275

Q26740278-91EE8627-BFF8-4D2E-B686-5D2A4F433583

P2860

Q26740278-00BA6C2F-6531-445F-90D6-98A9FF367FBA

Q26740278-024F8E13-C709-43B9-84B6-B5269FBBA867

Q26740278-030D5913-5E95-4AE4-A176-6D2C49816788

Q26740278-03AF5055-32A1-4862-BD7B-2E44A97B0EF3

Q26740278-10758F6C-A8DE-45A0-8F71-26C83B88600C

Q26740278-1726FD96-F6E9-4656-8FBD-EA2F2D43B837

Q26740278-2505F19F-0910-4781-B1CF-48BB8CACAE57

Q26740278-2508958B-5706-45C5-9BA8-170C258FA471

Q26740278-2780690C-AC04-4B8E-A09B-59D1C9A5E378

Q26740278-3128A2F0-E6E4-4AAF-B1A2-1E72B1714BC9

P2888

Q26740278-E3C0795A-844A-49F0-B939-B0367129DD8F

P304

Q26740278-60E9D1BF-8F8E-4C33-92EA-EB337DFBB15A

P31

Q26740278-7C93852F-305C-40E4-9959-F55356B0200C

Q26740278-DC25CA12-74D0-406E-8A5B-98CC8A406660

P3181

Q26740278-18BF8C03-409B-41E1-9DCA-726DA420E75C

P356

Q26740278-57E55D98-C8CE-4959-9847-BCE30DFD6C87

P407

Q26740278-EB513098-E145-4B05-9F41-CFBCC968D512

P433

Q26740278-EE143720-C351-459F-A4B4-E41D0673DE6B

P478

Q26740278-300B41F8-05A4-41E4-BD40-41EAFA50D903

P5008

Q26740278-9D6B3386-B7ED-4A4B-85DB-9DB22B66F412

P577

Q26740278-13334F42-8D35-4051-935C-CA48F7F2231E

P6179

Q26740278-98D2FD51-6060-43AB-84B0-54171C6D1D9B

P698

Q26740278-CECE4C47-8C94-405D-8105-FBD6BB958246

P921

Q26740278-092986AF-6C65-4D4B-B2D6-67CBB885AD24

Q26740278-9B3EF318-D6BC-42FD-A413-EF1167FD4EAC

Q26740278-B55D7CA7-6DD2-45B5-ACEE-1FF7B1EEDF5E

Q26740278-BC3624F9-1548-46DC-8F73-C3D25F7D8001

P932

Q26740278-FF086262-154C-447D-A41F-31C1AAA400EA

P3181

P356

S13045-016-0284-Z

P1433

Journal of Hematology & Oncology

P1476

Elotuzumab for the treatment of multiple myeloma

@en

P2093

David S Siegel

http://www.w3.org/2001/XMLSchema#string

Larysa Sanchez

http://www.w3.org/2001/XMLSchema#string

Michael L Wang

http://www.w3.org/2001/XMLSchema#string

Yucai Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

P2888

s13045-016-0284-z

P304

55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

75712

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13045-016-0284-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018711816

http://www.w3.org/2001/XMLSchema#string

P698

27417553

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

multiple myeloma

P932

4946088

http://www.w3.org/2001/XMLSchema#string